Illumina, Inc. (ILMN) Given Average Rating of “Hold” by Analysts
Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average rating of “Hold” from the twenty-four research firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $181.47.
Several equities research analysts have recently weighed in on ILMN shares. Deutsche Bank AG set a $175.00 target price on Illumina and gave the stock a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reaffirmed an “underweight” rating and issued a $122.00 target price (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research report on Wednesday, June 21st. Finally, Barclays PLC reaffirmed a “hold” rating and issued a $150.00 target price on shares of Illumina in a research report on Wednesday, July 19th.
Illumina (NASDAQ:ILMN) traded up 0.58% during midday trading on Friday, reaching $201.41. The company’s stock had a trading volume of 986,743 shares. The company has a market capitalization of $29.41 billion, a P/E ratio of 40.36 and a beta of 0.81. Illumina has a 1-year low of $119.37 and a 1-year high of $214.34. The company has a 50 day moving average of $199.76 and a 200-day moving average of $181.17.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. During the same quarter in the prior year, the business earned $0.86 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts anticipate that Illumina will post $3.65 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Given Average Rating of “Hold” by Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/24/illumina-inc-ilmn-given-average-rating-of-hold-by-analysts.html.
In other news, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $174.24, for a total transaction of $25,264.80. Following the sale, the senior vice president now directly owns 10,646 shares in the company, valued at approximately $1,854,959.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 22,540 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total value of $4,400,033.40. Following the sale, the director now owns 539,176 shares in the company, valued at $105,252,546.96. The disclosure for this sale can be found here. Insiders have sold a total of 175,188 shares of company stock worth $33,870,937 over the last quarter. Insiders own 1.60% of the company’s stock.
A number of hedge funds have recently modified their holdings of ILMN. Advisory Services Network LLC grew its holdings in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares in the last quarter. Penserra Capital Management LLC grew its holdings in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares in the last quarter. Paradigm Asset Management Co. LLC grew its holdings in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares in the last quarter. Patten Group Inc. grew its holdings in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. grew its holdings in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares in the last quarter. 93.32% of the stock is owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.